bcj201642a.pdf (517.6 kB)
Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.
journal contributionposted on 2016-11-15, 15:52 authored by H. S. Walter, S. Jayne, P. Mensah, F. M. Miall, M. Lyttelton, M. J. Dyer
[First paragraph] Obinutuzumab, an afucosylated, type 2 anti-CD20 antibody, showed superior results to rituximab in a head-to-head comparison in combination with chlorambucil in the first-line treatment of chronic lymphocytic leukaemia (CLL) patients with comorbidities in the CLL11 trial (NCT01010061).1 Enhanced activity of obinutuzumab in this setting may reflect better binding to Fc receptors as well as the direct activation of the lysosomal cell death pathway mediated by type 2 CD20 antibodies
We thank the patient and her family for participating in this clinical trial and the GP28331 study site staff on the Hope Unit at the Leicester Royal Infirmary. We also thank Dr Gregory Vosganian and his colleagues at Genentech and Roche for their help and review of the case. Studies were supported by the Leicester Experimental Cancer Medicine Centre (C325/A15575 Cancer Research UK/UK Department of Health).
CitationBlood Cancer Journal (2016) 6, e435;
Author affiliation/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cancer Studies and Molecular Medicine
- VoR (Version of Record)